← Insights

Expanded Access Programme in UAE Healthcare: Legal Guide

How the UAE's Expanded Access Programme lets patients with serious or life-threatening conditions access investigational medical products, and what it requires.

A guide to the legal framework, eligibility criteria, application process and stakeholder responsibilities under the UAE's Expanded Access Programme.

Reviewed by Mohamed Noureldin, Founder, Managing Partner & Senior Legal Consultant

Expanded Access Programme in UAE Healthcare: A Legal Guide

Related Services: Explore our healthcare legal services in the UAE and our medical malpractice advisory services for practical legal support in this area.

What Is the Expanded Access Programme in the UAE?

The expanded access UAE programme is part of the legal and regulatory environment the United Arab Emirates has built for its healthcare sector. Often referred to as compassionate use, it provides a pathway for patients with serious or life-threatening conditions to access investigational medical products that are not yet approved for general use.

The programme reflects the UAE's commitment to advanced medical solutions and to giving patients access to potentially life-saving treatments. Its design shows a proactive stance on public health and a healthcare system that aims to be both responsive and responsible, with every reasonable avenue for treatment explored.

The programme is not a stopgap measure. It is a defined system with clear eligibility criteria, application procedures and oversight mechanisms, all designed to safeguard patient well-being while promoting medical innovation. It sits where medical ethics, regulatory science and patient advocacy meet, and it addresses the practical complexities of pre-approval drug access.

The programme seeks to balance the need for rigorous clinical testing with the need to offer treatment options to patients with few alternatives. This position supports the UAE's standing in regional and global healthcare and helps attract patients and researchers. The programme also continues to evolve as new scientific knowledge and regulatory standards emerge, which helps keep the UAE at the forefront of medical innovation and patient care.

Legal Framework for the Expanded Access Programme in the UAE

The legal framework governing the Expanded Access Programme (EAP) in the UAE is multi-layered. It is primarily administered by the Ministry of Health and Prevention (MOHAP) and the recently established Emirates Drug Establishment (EDE). The framework is designed to manage potential risks to patients while facilitating access to investigational treatments, and all applications are scrutinised rigorously to maintain a high standard of patient safety.

Federal Decree-Law No. 38 of 2024 serves as a cornerstone of this framework, providing the statutory basis for the regulation of pharmaceutical products and establishments. This legislation empowers the regulatory authorities to design and implement programmes such as the EAP and to ensure that they are conducted in a controlled and ethical manner.

The regulations give the regulatory bodies significant authority to make determinations on a case-by-case basis. This allows flexibility in addressing the needs of patients with rare or life-threatening diseases. The UAE's approach to compassionate use is not an isolated policy; it is integrated into the broader national strategy for healthcare excellence. For more on pharmaceutical regulation, see our article on generic drug registration in the UAE.

The regulatory framework also includes guidelines on the roles and responsibilities of physicians, pharmaceutical companies and healthcare institutions, creating a clear chain of accountability. This helps ensure that investigational drugs are used with a high level of professionalism and ethical care.

The framework specifies the requirements for informed consent, so that patients are fully aware of the potential risks and benefits of the investigational treatment. This protects patient autonomy and upholds the ethical principles of medical practice.

The regulations also address liability, clarifying the legal responsibilities of all parties in the event of an adverse outcome. This gives physicians and pharmaceutical companies a degree of certainty, which is essential for their participation. The framework is subject to periodic review and revision so that it stays aligned with established international standards and responsive to the changing needs of the healthcare sector.

Key Requirements and Procedures

Eligibility Criteria

Eligibility for the Expanded Access Programme is strictly defined so that it serves its intended purpose. Patients must have a serious or immediately life-threatening disease or condition, and there must be no comparable or satisfactory alternative therapy to diagnose, monitor or treat the disease or condition. The patient must also be unable to obtain the investigational drug through participation in a clinical trial.

The treating physician must determine that the potential benefit to the patient justifies the potential risks of the treatment. This determination must be based on a thorough evaluation of the patient's medical history and the available scientific evidence. The process is meant to be both rigorous and compassionate. For related reading, see our article on competition law in the UAE healthcare sector.

Application and Review Process

The application process for the compassionate use UAE programme is carefully structured. It begins with the treating physician, who must submit a detailed application to the regulatory authorities. The application must include the patient's medical records, a justification for the use of the investigational drug and a treatment plan. The pharmaceutical company that manufactures the drug must also agree to provide it for compassionate use.

A panel of experts reviews each application against the established criteria. The review is designed to test the assumptions and justifications in the application, so that the decision rests on a sound and objective evaluation. The integrity of this process is essential to public trust in the programme.

Review timelines are also clearly defined, so that applications are processed promptly. This matters most for patients with rapidly progressing diseases, for whom any delay can have serious consequences. The regulations also provide for an appeals process, allowing physicians to challenge a negative decision. This adds a further layer of protection for patients and helps ensure that every application receives a fair and thorough hearing.

Roles and Responsibilities

The roles and responsibilities of each party in the Expanded Access Programme are clearly delineated:

  • The treating physician is responsible for the clinical management of the patient, including monitoring for adverse events and reporting them to the regulatory authorities.
  • The pharmaceutical company is responsible for providing the investigational drug and ensuring that it meets the required quality standards.
  • The healthcare institution is responsible for providing the necessary facilities and support for the treatment.

This division of labour removes ambiguity in how the programme is carried out. Our article on medical malpractice liability in the UAE looks more closely at the responsibilities of healthcare providers.

Stakeholder Key Responsibilities
Treating Physician Patient assessment, application submission, clinical management, adverse event reporting
Pharmaceutical Company Provision of investigational drug, quality assurance, technical support
Healthcare Institution Provision of facilities, administrative support, ethical oversight
Regulatory Authorities Application review, programme oversight, guideline enforcement

Compliance Monitoring and Enforcement

How Enforcement Works

Enforcement in the field of expanded access UAE operates through a multi-layered regulatory framework that requires precision from all market participants. UAE regulators have introduced increasingly sophisticated monitoring mechanisms to ensure compliance across all sectors. Federal authorities take a firm approach to non-compliance, using administrative penalties, licence suspensions and criminal prosecution where warranted.

Compliance requires more than registration. Businesses must put in place comprehensive internal governance frameworks that address all applicable regulatory requirements. Operators must maintain detailed records, implement robust complaint resolution mechanisms and adopt transparent operational structures that conform to UAE standards.

Enforcement follows a graduated escalation model. Initial violations typically result in administrative warnings and corrective orders. Repeated non-compliance triggers financial penalties that can reach significant thresholds. In cases involving serious violations, authorities may pursue criminal prosecution under applicable provisions.

Risk Mitigation for Healthcare Operators

Organisations operating within the scope of the expanded access UAE programme must take a proactive approach to risk, anticipating regulatory developments and addressing compliance gaps before they lead to enforcement action. The consequences of non-compliance far outweigh the costs of implementing robust compliance systems.

A sound risk mitigation strategy begins with a comprehensive regulatory audit that maps all applicable legal requirements against current operations. The audit must identify gaps, assess their severity and prioritise remediation based on enforcement risk and potential financial exposure. It should be conducted by qualified legal professionals who understand UAE regulatory enforcement and can design solutions for both current requirements and anticipated developments.

Automated compliance monitoring systems are a critical part of any effective risk mitigation programme. These systems must be designed to track regulatory changes, flag potential violations and generate compliance reports that demonstrate ongoing adherence to applicable requirements. Such systems create a documented compliance trail that can help answer enforcement action by showing good-faith efforts to stay compliant.

Strategic Implications of the Expanded Access Programme

The Expanded Access Programme has significant strategic implications for the UAE's healthcare sector. By providing a pathway for early access to advanced treatments, it enhances the UAE's reputation as a hub for medical excellence and a destination for advanced healthcare. It also strengthens the relationship between the UAE and the global pharmaceutical industry, encouraging companies to include the UAE in their clinical development plans.

The programme shows the UAE's ability to design complex regulatory solutions that are both patient-centred and business-friendly. Its demanding review process strengthens the credibility of the programme and the decisions made under it, which in turn builds confidence among patients, physicians and pharmaceutical companies. The programme's design also promotes a culture of continuous improvement across the wider healthcare system. For the business side of healthcare, our article on foreign investment in the UAE healthcare sector provides a comprehensive overview.

The programme also helps reduce the potential for a black market in unapproved drugs by providing a legal and regulated channel for access. It addresses the imbalance of information between patients and providers by requiring clear and transparent communication about the risks and benefits of the investigational treatment.

Data generated through the Expanded Access Programme can provide valuable real-world evidence on the safety and efficacy of investigational drugs. This data can inform future clinical trials and regulatory decisions. The programme may also help attract and retain top medical talent in the UAE, as it gives physicians the opportunity to work with advanced treatments and contribute to the development of new therapies. This, in turn, improves the quality of care available to all patients in the UAE, not just those enrolled in the programme.

Conclusion

The UAE's Expanded Access Programme is a critical component of its advanced healthcare system. It is a well-designed framework that provides a vital lifeline to patients with serious or life-threatening conditions. Its rigorous review process, its clear allocation of roles and responsibilities, and its alignment with the nation's broader healthcare goals all contribute to its effectiveness.

The programme demonstrates the UAE's commitment to fighting disease and to giving citizens and residents access to the most advanced medical treatments available, while balancing patient safety with innovation. For legal guidance on the UAE's healthcare regulations, contact Nour Attorneys. Our legal team can provide the strategic advice you need to achieve your objectives in this evolving sector.

Additional Resources

Explore more of our insights on related topics:

Call Us NowChat With Our Team On WhatsApp